Business
Coya Therapeutics Announces $11.1 Million Private Placement
HOUSTON, January 30, 2026--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte
About this update from Dr. Reddy's Laboratories Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/4deaba1b08bfe1ec200bacb3d4536381"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ejo9QCrmlkOpkmueSm8stA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4deaba1b08bfe1ec200bacb3d4536381","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/cC0nB9LIfSi.wCqpg05f8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/4deaba1b08bfe1ec200bacb3d4536381","width":1024,"height":512}},"lazy":false},{"type":"text","content":"- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment- Greenlight Capital, Coya’s largest institutional shareholder, is the only other investor participating in the offering","length":240,"tagName":"p","attribs":{}},{"type":"text","content":"HOUSTON, January 30, 2026--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expected to close on or about January 30, 2026, subject to the satisfaction of customary closing conditions. The investors in the offering are Dr. Reddy’s Laboratories, Inc. ($10 million) and Greenlight Capital ($1.1 million), an existing institutional stockholder of the Company.","length":810,"tagName":"p"},{"type":"text","content":"The gross proceeds to the Company from the private placement are expected to be approximately $11.1 million, before deducting offering expenses payable by the Company. No broker, placement agent or investment banker was engaged in the transaction. The Company intends to use the net proceeds to accelerate tech transfer and scale-up manufacturing activities for low dose IL-2 to support the commercial readiness of COYA 302.","length":424,"tagName":"p"...